HUP0400323A2 - Tyrosine kinase inhibitors and pharmaceutical compositions containing them - Google Patents
Tyrosine kinase inhibitors and pharmaceutical compositions containing themInfo
- Publication number
- HUP0400323A2 HUP0400323A2 HU0400323A HUP0400323A HUP0400323A2 HU P0400323 A2 HUP0400323 A2 HU P0400323A2 HU 0400323 A HU0400323 A HU 0400323A HU P0400323 A HUP0400323 A HU P0400323A HU P0400323 A2 HUP0400323 A2 HU P0400323A2
- Authority
- HU
- Hungary
- Prior art keywords
- alkyl
- heteroaryl
- aryl
- group
- nr60r61
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- -1 nitro, hydroxy Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 239000011593 sulfur Chemical group 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004419 alkynylene group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- OTXBWGUYZNKPMG-UHFFFAOYSA-N isofulminic acid Chemical compound O[N+]#[C-] OTXBWGUYZNKPMG-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000000126 substance Chemical group 0.000 abstract 1
- 125000005156 substituted alkylene group Chemical group 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány általános képletű vegyületekre - amelyek képletében Xnitrogén-, szénatom, alkilcsoport vagy kémiai kötés; Y oxigén- vagykénatom; W nitrogén-, szén-, oxigén- vagy kénatom, azzal amegkötéssel, hogy ha W oxigén- vagy kénatom, akkor R9 nincs jelen; R1.R2, R3, R4, R5, R6, R7, R8 és R9 hidrogén-, halogénatom, alkil-,alkenil-, alkinil-, cikloalkil-, heterocikloalkil-, amino-, OR60,nitro-, hidroxi-, -SR60, -NR60R61, ciano-, -CO2R60, -CONR60R61, -CO2-NR60R61, -NR62CONR60R61, -NR60SO2R61, -SO2NR60R61, -C(NR62)-NR60R61,aril-, heteroaril-, -(CH2)nOR60, -(CH2)nNR60R61, -(CH2)nSR60, -(CH2)n-aril, -(CH2)n-heteroaril, -(CH2)n-heterocikloalkil, -NH-Z-aril és -NH-Z-heteroaril csoport; ahol n értéke 1, 2 vagy 3; és Z adott esetbenszubsztituált alkilén-, alkenilén- vagy alkiniléncsoport, amely adottesetben egy vagy több CO, CNOH, CNOR60, CNNR60, CNNCOR60 és/vagyCNNSO2R60 csoportot tartalmaz; R60, R61 és R62 hidrogénatom, alkil-,alkenil-, alkinil-, cikloalkil-, cikloalkil-alkil-, hidroxi-, alkoxi-,aril-, heteroaril-, heteroaril-alkil-csoport, -alkil-R25 csoport; R25hidrogén-, halogénatom, alkenil-, hidroxi-, merkapto-, alkoxi-, alkil-tio-, amino-, alkil-amino-, dialkil-amino-, aril-, heteroaril-,ciano-, szulfinil-, szulfonilcsoport, -NR30COOR31, -NR30C(O)R31, -NR30SO2R31, -C(O)NR30R31, heteroaril vagy heterocikloalkil-csoport;valamint R30, R31 hidrogénatom, alkil-, cikloalkil-, -alkil-R25-csoport - és enantiomereikre, diasztereomereikre, gyógyszerészetilegelfogadható sóikra, hidrátjaikra, prodrugjaikra és szolvátjaikra,ezeket tartalmazó, tirozin-kináz enzimekkel kapcsolatos állapotok, rákés proliferatív betegségek kezelésére használhatógyógyszerkészítményekre vonatkozik.The invention applies to compounds of the general formula - whose formula contains a nitrogen, carbon atom, alkyl group or chemical bond; Y is an oxygen or sulfur atom; W is nitrogen, carbon, oxygen or sulfur, with the proviso that if W is oxygen or sulfur, then R9 is not present; R1.R2, R3, R4, R5, R6, R7, R8 and R9 are hydrogen, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, amino, OR60, nitro, hydroxy, -SR60 , -NR60R61, cyano-, -CO2R60, -CONR60R61, -CO2-NR60R61, -NR62CONR60R61, -NR60SO2R61, -SO2NR60R61, -C(NR62)-NR60R61,aryl-, heteroaryl-, -(CH2)nOR60, -(CH2 )nNR60R61, -(CH2)nSR60, -(CH2)n-aryl, -(CH2)n-heteroaryl, -(CH2)n-heterocycloalkyl, -NH-Z-aryl and -NH-Z-heteroaryl; where n is 1, 2 or 3; and Z is an optionally substituted alkylene, alkenylene or alkynylene group, optionally containing one or more CO, CNOH, CNOR60, CNNR60, CNNCOR60 and/or CNNSO2R60 groups; R60, R61 and R62 are hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, hydroxy, alkoxy, aryl, heteroaryl, heteroarylalkyl, -alkyl-R25; - NR30COOR31, -NR30C(O)R31, -NR30SO2R31, -C(O)NR30R31, heteroaryl or heterocycloalkyl group; as well as R30, R31 hydrogen atom, alkyl-, cycloalkyl-, -alkyl-R25 group - and their enantiomers, diastereomers, pharmaceutically acceptable applies to their salts, hydrates, prodrugs and solvates, medicinal preparations containing them for the treatment of conditions related to tyrosine kinase enzymes, cancer and proliferative diseases.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27932701P | 2001-03-28 | 2001-03-28 | |
PCT/US2002/009402 WO2002079192A1 (en) | 2001-03-28 | 2002-03-26 | Novel tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0400323A2 true HUP0400323A2 (en) | 2005-11-28 |
Family
ID=23068491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0400323A HUP0400323A2 (en) | 2001-03-28 | 2002-03-26 | Tyrosine kinase inhibitors and pharmaceutical compositions containing them |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1381598A4 (en) |
JP (1) | JP2004534010A (en) |
KR (1) | KR20030083016A (en) |
CN (1) | CN1514833A (en) |
AR (1) | AR035804A1 (en) |
BG (1) | BG108206A (en) |
BR (1) | BR0208373A (en) |
CA (1) | CA2442428A1 (en) |
CZ (1) | CZ20032615A3 (en) |
EE (1) | EE200300475A (en) |
GE (1) | GEP20053660B (en) |
HR (1) | HRP20030844A2 (en) |
HU (1) | HUP0400323A2 (en) |
IL (1) | IL158041A0 (en) |
IS (1) | IS6968A (en) |
MX (1) | MXPA03008690A (en) |
NO (1) | NO20034308L (en) |
PE (1) | PE20021015A1 (en) |
PL (1) | PL373300A1 (en) |
RU (1) | RU2003131693A (en) |
SK (1) | SK12002003A3 (en) |
UY (1) | UY27234A1 (en) |
WO (1) | WO2002079192A1 (en) |
YU (1) | YU84603A (en) |
ZA (1) | ZA200307466B (en) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7081454B2 (en) * | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
AU2003218236B2 (en) | 2002-03-01 | 2007-12-06 | Bristol-Myers Squibb Company | Transgenic non-human mammals expressing constitutively activated tyrosine kinase receptors |
AU2003243497A1 (en) * | 2002-06-12 | 2003-12-31 | Millennium Pharmaceuticals, Inc. | Antagonists of melanin concentrating hormone receptor |
WO2004050033A2 (en) * | 2002-12-02 | 2004-06-17 | Arqule, Inc. | Method of treating cancers |
EP1581539A4 (en) * | 2003-01-03 | 2007-09-19 | Bristol Myers Squibb Co | Novel tyrosine kinase inhibitors |
WO2004069160A2 (en) * | 2003-01-28 | 2004-08-19 | Smithkline Beecham Corporation | Chemical compounds |
US7312215B2 (en) | 2003-07-29 | 2007-12-25 | Bristol-Myers Squibb Company | Benzimidazole C-2 heterocycles as kinase inhibitors |
AU2004268621C1 (en) * | 2003-08-29 | 2011-08-18 | Exelixis, Inc. | c-Kit modulators and methods of use |
US20050075358A1 (en) * | 2003-10-06 | 2005-04-07 | Carboni Joan M. | Methods for treating IGF1R-inhibitor induced hyperglycemia |
DE102004010207A1 (en) | 2004-03-02 | 2005-09-15 | Aventis Pharma S.A. | New 4-benzimidazolyl-3(2H)-pyridazinone derivatives are kinase inhibitors, especially useful for treatment of cancer |
AP2139A (en) | 2004-04-02 | 2010-08-21 | Osi Pharm Inc | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors. |
US8101770B2 (en) * | 2004-12-16 | 2012-01-24 | Vertex Pharmaceuticals Incorporated | Pyridones useful as inhibitors of kinases |
US7393667B2 (en) | 2005-05-31 | 2008-07-01 | Bristol-Myers Squibb Company | Stereoselective reduction process for the preparation of pyrrolotriazine compounds |
AU2006278396A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Benzimidazole derivatives as sirtuin modulators |
US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US8088928B2 (en) | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
CA2620352A1 (en) * | 2005-08-29 | 2007-03-08 | Vertex Pharmaceuticals Incorporated | 3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases |
EP1919891B1 (en) * | 2005-08-29 | 2012-03-07 | Vertex Pharmaceuticals Incorporated | 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases |
EP1919905B1 (en) | 2005-08-29 | 2011-02-23 | Vertex Pharmaceuticals Incorporated | 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-recptor tyrosine kinases |
WO2007026720A1 (en) * | 2005-08-31 | 2007-03-08 | Taisho Pharmaceutical Co., Ltd. | Ring-fused pyrazole derivative |
US8575164B2 (en) | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
WO2007145203A1 (en) * | 2006-06-13 | 2007-12-21 | Daiichi Fine Chemical Co., Ltd. | Optically active 2-amino-1-(4-fluorophenyl)ethanol |
US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
WO2008022747A1 (en) * | 2006-08-21 | 2008-02-28 | F. Hoffmann-La Roche Ag | Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents |
WO2008025526A1 (en) * | 2006-08-31 | 2008-03-06 | F. Hoffmann-La Roche Ag | Indole derivatives, their manufacture and use as pharmaceutical agents |
US8492328B2 (en) | 2007-05-17 | 2013-07-23 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
TW200916472A (en) | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
CN101687840A (en) | 2007-06-25 | 2010-03-31 | 霍夫曼-拉罗奇有限公司 | Benzimidazole amido derivatives as kinase inhibitors |
EP2065380A1 (en) * | 2007-08-22 | 2009-06-03 | F.Hoffmann-La Roche Ag | Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer |
US7816540B2 (en) * | 2007-12-21 | 2010-10-19 | Hoffmann-La Roche Inc. | Carboxyl- or hydroxyl-substituted benzimidazole derivatives |
CA2712959C (en) | 2008-01-22 | 2015-06-23 | Vernalis (R & D) Ltd | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity |
WO2009143051A1 (en) | 2008-05-19 | 2009-11-26 | Osi Pharmaceuticals, Inc. | Substituted imidazopyr-and imidazotri-azines |
PE20120057A1 (en) | 2008-12-19 | 2012-02-24 | Sirtris Pharmaceuticals Inc | SIRTUINE MODULATING THIAZOLOPYRIDINE COMPOUNDS |
DE102010001064A1 (en) * | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and their use |
JP2012524119A (en) | 2009-04-20 | 2012-10-11 | オーエスアイ・ファーマシューティカルズ,エルエルシー | Preparation of C-pyrazine-methylamine |
US8536180B2 (en) * | 2009-05-27 | 2013-09-17 | Abbvie Inc. | Pyrimidine inhibitors of kinase activity |
EP2494070A2 (en) | 2009-10-30 | 2012-09-05 | Bristol-Myers Squibb Company | Methods for treating cancer in patients having igf-1r inhibitor resistance |
KR101594002B1 (en) * | 2010-10-06 | 2016-02-15 | 글락소스미스클라인 엘엘씨 | Benzimidazole derivatives as pi3 kinase inhibitors |
JP5789888B2 (en) * | 2010-11-01 | 2015-10-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Benzimidazole inhibitors of leukotriene formation |
EP2766497A1 (en) | 2011-10-13 | 2014-08-20 | Bristol-Myers Squibb Company | Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors |
KR102307566B1 (en) | 2013-06-21 | 2021-10-05 | 제니쓰 에피제네틱스 리미티드 | Novel bicyclic bromodomain inhibitors |
CN105492439B (en) | 2013-06-21 | 2019-11-22 | 齐尼思表观遗传学有限公司 | Substituted dicyclic compound as bromine structural domain inhibitor |
WO2015015318A2 (en) | 2013-07-31 | 2015-02-05 | Zenith Epigenetics Corp. | Novel quinazolinones as bromodomain inhibitors |
CN103936719A (en) * | 2014-05-14 | 2014-07-23 | 中国药科大学 | Preparation method and application of benzimidazoles derivatives |
CN108064274A (en) | 2014-07-30 | 2018-05-22 | 耶达研究及发展有限公司 | For cultivating the culture medium of multipotential stem cell |
US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
CN107207474B (en) | 2014-12-11 | 2021-05-07 | 恒翼生物医药科技(上海)有限公司 | Substituted heterocycles as bromodomain inhibitors |
US10231953B2 (en) | 2014-12-17 | 2019-03-19 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
US10179777B2 (en) * | 2015-04-16 | 2019-01-15 | Merck Patent Gmbh | 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives |
EP3914698A1 (en) | 2019-01-23 | 2021-12-01 | Yeda Research and Development Co. Ltd | Culture media for pluripotent stem cells |
CN117069696B (en) * | 2023-08-17 | 2024-04-26 | 中国药科大学 | Double-target small molecule inhibitor and preparation method and application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
SI1194425T1 (en) * | 1999-06-23 | 2005-12-31 | Sanofi Aventis Deutschland | Substituted benzimidazole |
US7081454B2 (en) * | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
-
2002
- 2002-03-26 CA CA002442428A patent/CA2442428A1/en not_active Abandoned
- 2002-03-26 MX MXPA03008690A patent/MXPA03008690A/en unknown
- 2002-03-26 PL PL02373300A patent/PL373300A1/en not_active Application Discontinuation
- 2002-03-26 EE EEP200300475A patent/EE200300475A/en unknown
- 2002-03-26 YU YU84603A patent/YU84603A/en unknown
- 2002-03-26 CN CNA028105168A patent/CN1514833A/en active Pending
- 2002-03-26 SK SK12002003A patent/SK12002003A3/en not_active Application Discontinuation
- 2002-03-26 GE GE5363A patent/GEP20053660B/en unknown
- 2002-03-26 BR BR0208373-6A patent/BR0208373A/en not_active IP Right Cessation
- 2002-03-26 JP JP2002577817A patent/JP2004534010A/en not_active Withdrawn
- 2002-03-26 WO PCT/US2002/009402 patent/WO2002079192A1/en active Application Filing
- 2002-03-26 HU HU0400323A patent/HUP0400323A2/en unknown
- 2002-03-26 EP EP02723631A patent/EP1381598A4/en not_active Withdrawn
- 2002-03-26 RU RU2003131693/04A patent/RU2003131693A/en not_active Application Discontinuation
- 2002-03-26 CZ CZ20032615A patent/CZ20032615A3/en unknown
- 2002-03-26 KR KR10-2003-7012594A patent/KR20030083016A/en not_active Application Discontinuation
- 2002-03-26 IL IL15804102A patent/IL158041A0/en unknown
- 2002-03-27 PE PE2002000244A patent/PE20021015A1/en not_active Application Discontinuation
- 2002-03-27 UY UY27234A patent/UY27234A1/en not_active Application Discontinuation
- 2002-03-27 AR ARP020101167A patent/AR035804A1/en not_active Application Discontinuation
-
2003
- 2003-09-25 ZA ZA200307466A patent/ZA200307466B/en unknown
- 2003-09-26 BG BG108206A patent/BG108206A/en unknown
- 2003-09-26 NO NO20034308A patent/NO20034308L/en not_active Application Discontinuation
- 2003-09-26 IS IS6968A patent/IS6968A/en unknown
- 2003-10-17 HR HR20030844A patent/HRP20030844A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IL158041A0 (en) | 2004-03-28 |
BR0208373A (en) | 2005-02-22 |
SK12002003A3 (en) | 2004-10-05 |
EP1381598A4 (en) | 2008-03-19 |
MXPA03008690A (en) | 2003-12-12 |
YU84603A (en) | 2006-03-03 |
CZ20032615A3 (en) | 2004-03-17 |
RU2003131693A (en) | 2005-05-10 |
UY27234A1 (en) | 2002-10-31 |
CN1514833A (en) | 2004-07-21 |
EP1381598A1 (en) | 2004-01-21 |
IS6968A (en) | 2003-09-26 |
AR035804A1 (en) | 2004-07-14 |
WO2002079192A1 (en) | 2002-10-10 |
JP2004534010A (en) | 2004-11-11 |
NO20034308L (en) | 2003-11-26 |
GEP20053660B (en) | 2005-11-10 |
BG108206A (en) | 2004-11-30 |
KR20030083016A (en) | 2003-10-23 |
CA2442428A1 (en) | 2002-10-10 |
NO20034308D0 (en) | 2003-09-26 |
ZA200307466B (en) | 2005-01-13 |
HRP20030844A2 (en) | 2005-08-31 |
EE200300475A (en) | 2004-02-16 |
PL373300A1 (en) | 2005-08-22 |
PE20021015A1 (en) | 2002-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0400323A2 (en) | Tyrosine kinase inhibitors and pharmaceutical compositions containing them | |
CY1107915T1 (en) | TRYCYCLIC COPYRIPES OR SPYROPYRROLIDES | |
HUP0401783A2 (en) | 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands, their use and pharmaceutical compositions containing them | |
CY1108894T1 (en) | NEW PRODUCERS OF VENZIMIDAZOL | |
DE60226912D1 (en) | Quinoline and chianzoline derivatives for the treatment of tumors | |
HUP0402225A2 (en) | Macrolide-compounds, process for their preparation and pharmaceutical compositions containing them | |
PE20040155A1 (en) | AMINOINAZOLE DERIVATIVES, PREPARATION PROCEDURE AND INTERMEDIATES OF THIS PROCEDURE AS A DRUGS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
HUP0300838A2 (en) | Novel heteroaryl derivatives, process for their preparation and the use thereof as pharmaceuticals | |
CY1106521T1 (en) | 17BETA-HYDROXYSTEPOID DEHYDROGENATE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES | |
HUP0500573A2 (en) | Triphenyl-ethylene derivatives as selective estrogen receptor modulators and pharmaceutical compositions containing the same | |
HUP0401009A2 (en) | 1-aryl-or 1-alkylsulfonylbenzole derivatives as 5-hydroxytryptamine-6 ligands, process for their preparation and pharmaceutical compositions containing them | |
CY1107677T1 (en) | Derivatives of 1- [INDOL-3-YL) CARBONYL] PIPERAZINE | |
ATE307810T1 (en) | IMIDAZOLE-2-CARBONIC ACID AMIDE DERIVATIVES AS RAF-KINASE INHIBITORS | |
NO20054361D0 (en) | Benzenesylphonamide derivatives, methods of preparation and use thereof for treating pain | |
AP1816A (en) | 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists. | |
ATE501128T1 (en) | 1,2,3-TRIAZOLAMIDE DERIVATIVES AS INHIBITORS OF CYTOKINE PRODUCTION | |
HUP0203054A2 (en) | Farnesyl protein transferase inhibitors, pharmaceutical compositions containing them and their use | |
ATE498600T1 (en) | INDENE DERIVATIVES AS PHARMACEUTICALS | |
HUP0400341A2 (en) | Cyano-substituted dihydropyrimidine compounds and their use | |
ATE482933T1 (en) | SULFOPYRROL DERIVATIVES | |
NO20034215L (en) | Novel amides, preparation and therapeutic use of modulators of CCR receptor activity | |
DE60237512D1 (en) | N- (ARYL) -2-ARYLETHESULFONAMIDES AND THEIR THERAPEUTIC APPLICATIONS | |
ATE315563T1 (en) | PIPERIDINYLMORPHOLINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | |
HUP0303186A2 (en) | 4-aminobenzopyran derivatives | |
HUP0301551A2 (en) | New use of 5ht3 and neuronal nicotinicreceptor antagonist 1-amino-alkycyclohexanes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |